Kairos Pharma Ltd. (NYSE American: KAPA) will take a prominent role at the 24th Annual Discovery on Target Drug Discovery Conference, scheduled for September 28 to October 1 in Boston, where President and Chief Scientific Officer Neil Bhowmick will present and moderate a discussion. The company's participation signals its growing influence in the oncology therapeutic space and highlights its unique approach to addressing one of the most persistent challenges in cancer treatment: drug resistance.
Bhowmick will moderate a breakout session on September 30 titled "Winning the Race against Cancer Therapy Resistance," which will focus on Kairos' strategy of targeting cancer drug resistance to extend the efficacy of previously effective drug candidates. This session is particularly significant because it positions Kairos at the forefront of a critical area in oncology—finding ways to revive the effectiveness of therapies that have stopped working due to resistance mechanisms. For investors, this underscores the company's potential to develop treatments that could address large unmet needs and capture significant market share.
In addition, Bhowmick will deliver an oral plenary presentation on September 30 at 2:35 p.m. Eastern on KROS-101, Kairos' drug candidate targeting solid tumors. The presentation will focus on KROS-101's targeting of GITR (Glucocorticoid-Induced TNF Receptor) to increase T-cell function and expand effector T-cells with anti-tumor activity. This mechanism of action is noteworthy because it aims to harness the body's immune system to fight cancer more effectively, a promising avenue that has garnered substantial attention from researchers and pharmaceutical companies alike. If successful, KROS-101 could become a valuable addition to the immuno-oncology arsenal, offering new hope for patients with solid tumors.
The implications of this announcement extend beyond the scientific community. For Kairos Pharma, presenting at such a prestigious conference provides a platform to showcase its research to a wide audience of industry experts, potential partners, and investors. It also reinforces the company's commitment to advancing its pipeline and could serve as a catalyst for future collaborations or funding opportunities. As a relatively small player in the competitive oncology space, Kairos' ability to generate buzz around its innovative approach is crucial for its growth and recognition.
Based in Los Angeles, California, Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. This dual focus on ENV-105 and KROS-101 demonstrates Kairos' multifaceted strategy to tackle cancer from different angles, potentially increasing its chances of clinical success.
For investors and industry observers, Kairos' participation in the Discovery on Target conference is a clear signal of its scientific credibility and its potential to make a meaningful impact in oncology. The latest news and updates relating to KAPA are available in the company's newsroom at https://nnw.fm/KAPA. Additionally, the full press release can be viewed at https://nnw.fm/DoHxL. As the conference approaches, the market will be watching closely to see how Kairos' presentations are received and what they might mean for the future of cancer therapy.
NetworkNewsWire, a specialized communications platform with a focus on financial news and content distribution, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. The platform also offers editorial syndication to 5,000+ outlets and social media distribution via IBN to millions of social media followers. For more information, please visit NetworkNewsWire.
